Ikarian Capital
Latest statistics and disclosures from Ikarian Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BIIB, ALNY, CRSP, NTLA, APLS, and represent 28.98% of Ikarian Capital's stock portfolio.
- Added to shares of these 10 stocks: ALNY (+$84M), NTLA (+$48M), CRSP (+$43M), APLS (+$38M), SAVA (+$32M), CCXI (+$13M), RETA (+$9.8M), ALEC (+$9.6M), CGEM (+$7.6M), KOD (+$6.7M).
- Started 21 new stock positions in ATNX, CRTX, NTLA, RDNT, Onconova Therapeutics, OTIC, Quantum Si, AFMD, CMLF, BCEL. Synaptogenix, ALNY, Anebulo Pharmaceuticals, ABCL, Tempest Therapeutics, KOD, SAVA, CMMB, APLS, HEPA, JETS.
- Reduced shares in these 10 stocks: , , ARKK (-$132M), IWM (-$99M), TLT (-$95M), MRNA (-$92M), ARKG (-$64M), QQQ (-$64M), BGNE (-$60M), NVAX (-$56M).
- Sold out of its positions in ARKK, ACHV, MSOS, AGIO, ALBO, ALVR, ALT, ABUS, ARDX, ARGX.
- Ikarian Capital was a net seller of stock by $-1.7B.
- Ikarian Capital has $1.2B in assets under management (AUM), dropping by -58.37%.
- Central Index Key (CIK): 0001778253
Tip: Access up to 7 years of quarterly data
Positions held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ikarian Capital
Companies in the Ikarian Capital portfolio as of the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Biogen Idec (BIIB) | 11.1 | $137M | 396k | 346.28 | ||
| Alnylam Pharmaceuticals Put Option (ALNY) | 6.8 | $84M | NEW | 496k | 169.52 | |
| Crispr Therapeutics Namen Akt (CRSP) | 4.2 | $52M | +461% | 320k | 161.89 | |
| Intellia Therapeutics Call Option (NTLA) | 3.9 | $48M | NEW | 294k | 161.91 | |
| Apellis Pharmaceuticals Call Option (APLS) | 3.1 | $38M | NEW | 600k | 63.20 | |
| Celldex Therapeutics Com New (CLDX) | 2.7 | $33M | -10% | 982k | 33.44 | |
| Cassava Sciences (SAVA) | 2.6 | $32M | NEW | 370k | 85.42 | |
| Sage Therapeutics Put Option (SAGE) | 2.3 | $29M | +13% | 504k | 56.81 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 2.3 | $29M | -51% | 305k | 93.64 | |
| Reata Pharmaceuticals Cl A Put Option (RETA) | 2.0 | $25M | +65% | 175k | 141.54 | |
| Bausch Health Companies Put Option (BHC) | 1.9 | $24M | 800k | 29.32 | ||
| Chemocentryx Call Option (CCXI) | 1.8 | $22M | +133% | 1.7M | 13.39 | |
| Galapagos Nv Spon Adr (GLPG) | 1.7 | $21M | 300k | 69.33 | ||
| Macrogenics Call Option (MGNX) | 1.6 | $20M | +8% | 760k | 26.85 | |
Setup an alertIkarian Capital will file the next quarterly 13-HR in about 2 months. Would you like to be notified? |
||||||
| Incyte Corporation Call Option (INCY) | 1.6 | $20M | +6% | 237k | 84.12 | |
| Intra Cellular Therapies Call Option (ITCI) | 1.5 | $18M | -28% | 441k | 40.82 | |
| X4 Pharmaceuticals (XFOR) | 1.4 | $18M | +3% | 2.7M | 6.50 | |
| Tracon Pharmaceuticals Com New (TCON) | 1.4 | $18M | 2.7M | 6.49 | ||
| Zogenix Com New (ZGNX) | 1.4 | $17M | 974k | 17.28 | ||
| Relmada Therapeutics Call Option (RLMD) | 1.3 | $16M | +3% | 504k | 32.01 | |
| Ocular Therapeutix (OCUL) | 1.3 | $16M | +64% | 1.1M | 14.18 | |
| Xenon Pharmaceuticals (XENE) | 1.2 | $15M | +3% | 820k | 18.62 | |
| Alector Put Option (ALEC) | 1.2 | $15M | +179% | 719k | 20.85 | |
| Ark Etf Tr Genomic Rev Etf (ARKG) | 1.2 | $15M | -81% | 161k | 92.50 | |
| Allakos Put Option (ALLK) | 1.0 | $13M | +34% | 151k | 85.36 | |
| Chimerix (CMRX) | 1.0 | $13M | -9% | 1.6M | 8.00 | |
| Seres Therapeutics Call Option (MCRB) | 1.0 | $12M | -55% | 500k | 23.85 | |
| Fibrogen Put Option (FGEN) | 1.0 | $12M | +47% | 444k | 26.63 | |
| Rapt Therapeutics Put Option (RAPT) | 0.9 | $11M | +40% | 350k | 31.79 | |
| Milestone Pharmaceuticals (MIST) | 0.9 | $11M | +7% | 2.0M | 5.50 | |
| Sierra Oncology Com New (SRRA) | 0.9 | $11M | +22% | 545k | 19.50 | |
| Arena Pharmaceuticals Com New Call Option (ARNA) | 0.8 | $10M | 150k | 68.20 | ||
| Vaxcyte (PCVX) | 0.8 | $10M | -10% | 448k | 22.51 | |
| Iovance Biotherapeutics (IOVA) | 0.8 | $9.8M | +87% | 375k | 26.02 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.7 | $9.0M | +7% | 1.4M | 6.64 | |
| Fate Therapeutics Put Option (FATE) | 0.7 | $9.0M | -7% | 104k | 86.80 | |
| Annovis Bio (ANVS) | 0.7 | $8.9M | -46% | 104k | 85.58 | |
| Gossamer Bio (GOSS) | 0.7 | $8.5M | -22% | 1.0M | 8.12 | |
| Cabaletta Bio (CABA) | 0.7 | $8.1M | +143% | 947k | 8.60 | |
| Cullinan Oncology (CGEM) | 0.6 | $7.6M | +29459% | 296k | 25.75 | |
| Adc Therapeutics Sa SHS Call Option (ADCT) | 0.6 | $7.3M | 300k | 24.35 | ||
| Odonate Therapeutics Ord (ODT) | 0.6 | $6.9M | +48% | 2.0M | 3.49 | |
| Immunovant (IMVT) | 0.5 | $6.8M | +6% | 643k | 10.57 | |
| Arcus Biosciences Incorporated Put Option (RCUS) | 0.5 | $6.7M | 246k | 27.46 | ||
| Kodiak Sciences Call Option (KOD) | 0.5 | $6.7M | NEW | 72k | 93.00 | |
| Scpharmaceuticals (SCPH) | 0.5 | $6.7M | -16% | 1.1M | 6.11 | |
| Clovis Oncology (CLVS) | 0.5 | $6.6M | +66% | 1.1M | 5.80 | |
| Protara Therapeutics Com Stk (TARA) | 0.5 | $5.7M | -9% | 585k | 9.74 | |
| Verastem (VSTM) | 0.5 | $5.7M | -48% | 1.4M | 4.07 | |
| Vincerx Pharma Com New (VINC) | 0.4 | $5.5M | -2% | 427k | 12.99 | |
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.4 | $5.5M | NEW | 291k | 19.02 | |
| Shattuck Labs (STTK) | 0.4 | $5.5M | 190k | 28.99 | ||
| Gilead Sciences Call Option (GILD) | 0.4 | $5.5M | -81% | 80k | 68.86 | |
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $5.1M | -64% | 210k | 24.39 | |
| Lyra Therapeutics (LYRA) | 0.4 | $5.0M | -19% | 625k | 8.03 | |
| Etf Ser Solutions Us Glb Jets Call Option (JETS) | 0.4 | $4.8M | NEW | 200k | 24.18 | |
| Finch Therapeutics (FNCH) | 0.4 | $4.6M | +116% | 325k | 14.07 | |
| Satsuma Pharmaceuticals Ord (STSA) | 0.4 | $4.5M | -4% | 644k | 7.05 | |
| Ovid Therapeutics (OVID) | 0.4 | $4.4M | 1.1M | 3.91 | ||
| Chardan Healthcr Acqstn 2 Unit 99/99/9999 (CHAQ.U) | 0.4 | $4.4M | 400k | 10.92 | ||
| Nextcure (NXTC) | 0.3 | $4.2M | +13% | 517k | 8.03 | |
| Ascendis Pharma A/s Sponsored Adr Call Option (ASND) | 0.3 | $4.0M | -73% | 30k | 131.63 | |
| Sarepta Therapeutics Call Option (SRPT) | 0.3 | $3.9M | -91% | 50k | 77.74 | |
| Tg Therapeutics Put Option (TGTX) | 0.3 | $3.9M | 100k | 38.78 | ||
| I Mab Sponsored Ads (IMAB) | 0.3 | $3.9M | -81% | 46k | 83.94 | |
| RadNet (RDNT) | 0.3 | $3.7M | NEW | 111k | 33.69 | |
| Kadmon Hldgs (KDMN) | 0.3 | $3.6M | 937k | 3.87 | ||
| Dbv Technologies S A Sponsored Adr (DBVT) | 0.3 | $3.6M | 323k | 11.01 | ||
| Aileron Therapeutics (ALRN) | 0.3 | $3.5M | 2.8M | 1.25 | ||
| Phathom Pharmaceuticals (PHAT) | 0.3 | $3.4M | 100k | 33.86 | ||
| Tricida (TCDA) | 0.3 | $3.3M | 775k | 4.32 | ||
| Synlogic (SYBX) | 0.3 | $3.3M | -43% | 848k | 3.89 | |
| Amicus Therapeutics (FOLD) | 0.3 | $3.3M | 342k | 9.64 | ||
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $3.2M | -62% | 85k | 38.15 | |
| Pliant Therapeutics (PLRX) | 0.3 | $3.2M | 109k | 29.12 | ||
| Viking Therapeutics (VKTX) | 0.3 | $3.1M | -27% | 525k | 5.99 | |
| Bellus Health Com New (BLU) | 0.3 | $3.1M | +152% | 1.0M | 3.11 | |
| Bioatla (BCAB) | 0.2 | $3.0M | 70k | 42.39 | ||
| Eyepoint Pharmaceuticals Com New Call Option (EYPT) | 0.2 | $3.0M | 329k | 8.99 | ||
| Synaptogenix Com New | 0.2 | $3.0M | NEW | 300k | 9.85 | |
| Cerecor (CERC) | 0.2 | $2.9M | 897k | 3.27 | ||
| Vistagen Therapeutics Com New (VTGN) | 0.2 | $2.9M | -68% | 917k | 3.15 | |
| Aerpio Pharmaceuticals (ARPO) | 0.2 | $2.8M | -36% | 1.7M | 1.69 | |
| Cm Life Sciences Com Cl A (CMLF) | 0.2 | $2.8M | NEW | 200k | 14.02 | |
| Eledon Pharmaceuticals (ELDN) | 0.2 | $2.8M | +40% | 350k | 7.91 | |
| Gemini Therapeutics (GMTX) | 0.2 | $2.8M | -37% | 427k | 6.47 | |
| Alpine Immune Sciences (ALPN) | 0.2 | $2.7M | 301k | 9.00 | ||
| Hepion Pharmaceuticals (HEPA) | 0.2 | $2.7M | NEW | 1.4M | 1.98 | |
| Savara (SVRA) | 0.2 | $2.7M | -7% | 1.6M | 1.70 | |
| Immatics SHS (IMTX) | 0.2 | $2.6M | -11% | 225k | 11.61 | |
| Allogene Therapeutics Call Option (ALLO) | 0.2 | $2.6M | -14% | 100k | 26.09 | |
| Cel-sci Corp Com Par New Call Option (CVM) | 0.2 | $2.6M | +180% | 300k | 8.68 | |
| Inmune Bio Ord (INMB) | 0.2 | $2.6M | -37% | 147k | 17.57 | |
| Yumanity Therapeutics (YMTX) | 0.2 | $2.6M | 220k | 11.66 | ||
| Liquidia Corporation Com New (LQDA) | 0.2 | $2.5M | -6% | 890k | 2.86 | |
| Catalyst Biosciences Com New (CBIO) | 0.2 | $2.5M | 581k | 4.33 | ||
| Sutro Biopharma (STRO) | 0.2 | $2.5M | -59% | 135k | 18.58 | |
| Solid Biosciences (SLDB) | 0.2 | $2.5M | +2760% | 676k | 3.66 | |
| Cytokinetics Com New (CYTK) | 0.2 | $2.4M | -4% | 121k | 19.79 | |
| Kalvista Pharmaceuticals (KALV) | 0.2 | $2.3M | -67% | 97k | 23.96 | |
| Madrigal Pharmaceuticals (MDGL) | 0.2 | $2.3M | 24k | 97.36 | ||
| Icad Com New (ICAD) | 0.2 | $2.2M | -41% | 128k | 17.32 | |
| Atreca Cl A Com (BCEL) | 0.2 | $2.1M | NEW | 250k | 8.52 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.2 | $2.0M | 200k | 10.20 | ||
| Cyclerion Therapeutics (CYCN) | 0.2 | $2.0M | +69% | 510k | 3.90 | |
| Inflarx Nv (IFRX) | 0.2 | $2.0M | -4% | 667k | 2.97 | |
| Casi Pharmaceuticalsinc Com Stk (CASI) | 0.2 | $2.0M | 1.3M | 1.55 | ||
| Quantum Si Com Cl A | 0.2 | $2.0M | NEW | 160k | 12.26 | |
| Trillium Therapeutics Com New Call Option (TRIL) | 0.2 | $1.9M | 200k | 9.70 | ||
| Passage Bio (PASG) | 0.2 | $1.9M | 146k | 13.25 | ||
| Vascular Biogenics (VBLT) | 0.2 | $1.9M | 801k | 2.39 | ||
| Black Diamond Therapeutics (BDTX) | 0.2 | $1.9M | 154k | 12.19 | ||
| Diamedica Therapeutics Com New (DMAC) | 0.1 | $1.8M | 415k | 4.45 | ||
| Corbus Pharmaceuticals Hldgs (CRBP) | 0.1 | $1.8M | 964k | 1.83 | ||
| Mustang Bio (MBIO) | 0.1 | $1.7M | 526k | 3.32 | ||
| Fulcrum Therapeutics (FULC) | 0.1 | $1.7M | -61% | 163k | 10.48 | |
| Frequency Therapeutics (FREQ) | 0.1 | $1.7M | -52% | 171k | 9.96 | |
| Bellicum Pharmaceuticals Com New (BLCM) | 0.1 | $1.7M | 500k | 3.30 | ||
| Applied Genetic Technol Corp C (AGTC) | 0.1 | $1.6M | 416k | 3.91 | ||
| Abcellera Biologics Call Option (ABCL) | 0.1 | $1.6M | NEW | 74k | 21.99 | |
| Aclaris Therapeutics (ACRS) | 0.1 | $1.6M | -52% | 90k | 17.56 | |
| Harpoon Therapeutics (HARP) | 0.1 | $1.6M | -57% | 114k | 13.87 | |
| Ac Immune Sa SHS (ACIU) | 0.1 | $1.6M | +63% | 196k | 7.93 | |
| Atyr Pharma Com New (LIFE) | 0.1 | $1.5M | 300k | 4.88 | ||
| Auris Medical Holding SHS (EARS) | 0.1 | $1.4M | -12% | 405k | 3.57 | |
| Clene Common Stock (CLNN) | 0.1 | $1.3M | 119k | 11.25 | ||
| Eli Lilly & Co. (LLY) | 0.1 | $1.3M | -95% | 5.7k | 229.70 | |
| Adicet Bio (ACET) | 0.1 | $1.3M | -7% | 126k | 10.28 | |
| Anebulo Pharmaceuticals | 0.1 | $1.2M | NEW | 175k | 6.89 | |
| Catabasis Pharmaceuticals In Com New (CATB) | 0.1 | $1.1M | -37% | 532k | 2.11 | |
| Brainstorm Cell Therapeutics Com New (BCLI) | 0.1 | $1.1M | 293k | 3.80 | ||
| Cortexyme (CRTX) | 0.1 | $1.1M | NEW | 21k | 52.99 | |
| Merus N V (MRUS) | 0.1 | $1.1M | -53% | 51k | 21.06 | |
| Regulus Therapeutics Com New (RGLS) | 0.1 | $1.0M | 1.2M | 0.81 | ||
| Tempest Therapeutics | 0.1 | $1.0M | NEW | 90k | 11.18 | |
| Panbela Therapeutics (PBLA) | 0.1 | $976k | 345k | 2.83 | ||
| Oncternal Therapeutics (ONCT) | 0.1 | $950k | -56% | 200k | 4.75 | |
| Athenex (ATNX) | 0.1 | $923k | NEW | 200k | 4.62 | |
| Immunoprecise Antibodies Com New (IPA) | 0.1 | $903k | 150k | 6.02 | ||
| Poseida Therapeutics I (PSTX) | 0.1 | $861k | 86k | 10.03 | ||
| Affimed Therapeutics B V (AFMD) | 0.1 | $792k | NEW | 93k | 8.51 | |
| Bcls Acquisition Corp Com Cl A (BLSA) | 0.1 | $791k | 75k | 10.53 | ||
| Stealth Biotherapeutics Corp Sponsored Ads (MITO) | 0.1 | $761k | -38% | 488k | 1.56 | |
| Vallon Pharmaceuticals (VLON) | 0.1 | $761k | 140k | 5.44 | ||
| Frazier Lifesciences Acqu Unit 12/09/2025 (FLACU) | 0.1 | $756k | 75k | 10.08 | ||
| Apricus Biosciences (SEEL) | 0.1 | $739k | -61% | 280k | 2.64 | |
| Intercept Pharmaceuticals In (ICPT) | 0.1 | $700k | -74% | 35k | 20.00 | |
| C4 Therapeutics Com Stk (CCCC) | 0.1 | $666k | -84% | 18k | 37.84 | |
| Orchard Therapeutics Ads (ORTX) | 0.1 | $659k | -40% | 150k | 4.39 | |
| Ocuphire Pharma (OCUP) | 0.1 | $632k | 120k | 5.29 | ||
| Stoke Therapeutics Put Option (STOK) | 0.0 | $606k | -82% | 18k | 33.67 | |
| Cyclacel Pharmaceuticals (CYCC) | 0.0 | $593k | -66% | 100k | 5.93 | |
| Agenus Com New (AGEN) | 0.0 | $570k | -84% | 104k | 5.49 | |
| Novavax Com New (NVAX) | 0.0 | $559k | -99% | 2.6k | 212.06 | |
| Anaptysbio Inc Common (ANAB) | 0.0 | $558k | -88% | 22k | 25.89 | |
| Delcath Sys Com New (DCTH) | 0.0 | $555k | 44k | 12.64 | ||
| Larimar Therapeutics (LRMR) | 0.0 | $520k | -87% | 53k | 9.82 | |
| Puma Biotechnology (PBYI) | 0.0 | $504k | 55k | 9.18 | ||
| Otonomy (OTIC) | 0.0 | $472k | NEW | 212k | 2.23 | |
| Genocea Biosciences Com New (GNCA) | 0.0 | $468k | +153% | 200k | 2.34 | |
| Chiasma (CHMA) | 0.0 | $428k | -85% | 90k | 4.73 | |
| Cara Therapeutics (CARA) | 0.0 | $418k | -97% | 29k | 14.25 | |
| Vericel Call Option (VCEL) | 0.0 | $416k | 7.9k | 52.66 | ||
| Aptose Biosciences Com New (APTO) | 0.0 | $346k | 104k | 3.33 | ||
| Mereo Biopharma Group Ads (MREO) | 0.0 | $346k | -17% | 944k | 0.37 | |
| Cogent Biosciences (COGT) | 0.0 | $338k | 42k | 8.09 | ||
| Chardan Healthcr Acqstn 2 (CHAQ) | 0.0 | $300k | 30k | 10.00 | ||
| Zai Lab Adr Call Option (ZLAB) | 0.0 | $284k | -90% | 1.6k | 177.50 | |
| Assembly Biosciences (ASMB) | 0.0 | $281k | 73k | 3.88 | ||
| Corvus Pharmaceuticals (CRVS) | 0.0 | $267k | 100k | 2.67 | ||
| Aslan Pharmaceuticals Ads (ASLN) | 0.0 | $248k | 1.2M | 0.20 | ||
| Inhibrx (INBX) | 0.0 | $222k | 8.1k | 27.49 | ||
| Inventiva Sa Ads (IVA) | 0.0 | $207k | 15k | 13.80 | ||
| Gamida Cell SHS (GMDA) | 0.0 | $201k | -77% | 31k | 6.45 | |
| Onconova Therapeutics Com New | 0.0 | $161k | NEW | 23k | 6.93 | |
| Soleno Therapeutics Com New (SLNO) | 0.0 | $140k | 123k | 1.14 | ||
| Baudax Bio (BXRX) | 0.0 | $76k | 100k | 0.76 | ||
Past Filings by Ikarian Capital
SEC 13F filings are viewable for Ikarian Capital going back to 2019
- Ikarian Capital 2021 Q1 restated filed Aug. 18, 2021
- Ikarian Capital 2021 Q2 restated filed Aug. 18, 2021
- Ikarian Capital 2021 Q2 filed Aug. 16, 2021
- Ikarian Capital 2021 Q1 filed May 17, 2021
- Ikarian Capital 2020 Q4 filed Feb. 12, 2021
- Ikarian Capital 2020 Q3 filed Nov. 16, 2020
- Ikarian Capital 2020 Q2 filed Aug. 14, 2020
- Ikarian Capital 2020 Q1 filed May 15, 2020
- Ikarian Capital 2019 Q4 filed Jan. 31, 2020